Project Grant HT94252510271
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
The Department of Defense's Defense Health Agency awarded a $1,205,784 Project Grant to Queensland University of Technology (QUT) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "ACCELERATING TRANSLATION OF A NOVEL METAP2 INHIBITOR IN TREATMENT-RESISTANT AND AGGRESSIVE-VARIANT PROSTATE CANCER," runs from July 1, 2024 to June 30, 2027. The project aims to accelerate the translation of a novel MetAP2 inhibitor therapy for treating...
This Project Grant award of $231,009.44 from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) supports research at the University of Adelaide in Australia to understand heterogeneity and improve the precision of prostate cancer clinical outcomes. The 3-year project, which runs from September 1, 2023 to August 31, 2026, aims to advance scientific understanding and develop new treatments related to prostate cancer, a key health condition affecting...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
The University of Adelaide in Australia was awarded a $1,005,845 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from September 2022 through September 2025 to exploit prostate cancer metabolic dependencies to develop new therapeutics and circulating prognostic and predictive biomarkers. The Military Medical Research and Development program supports basic, applied, and...
This federal Project Grant award of $1,602,137.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research at the University of Kentucky Research Foundation to target the MNK/GRP78 pathway to disrupt proteostasis rewiring in castration-resistant prostate cancer. The research aims to transform healthcare for military service members and the broader public by exploring innovative approaches to disease prevention,...
This $188,000 Project Grant was awarded on April 1, 2024 by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), to The Institute For Cancer Research. The grant funds a research project titled "P2X7 RECEPTOR AS A NOVEL THERAPEUTIC TARGET IN PROSTATE CANCER" that will be conducted from April 1, 2024 through March 31, 2026. The Institute For Cancer Research, a non-profit subsidiary of Temple University, will carry out biomedical research...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...
This federal Project Grant award in the amount of $1,927,373.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to develop targeted therapies for metastatic prostate cancers classified by subtypes of DNA repair deficiency. The primary awardee is the Fred Hutchinson Cancer Center, a prominent non-profit medical research organization located in Seattle, Washington. The grant has a performance...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...